CEO of Cloud Software Company Anaplan on Stock's NYSE Debut
*By Christian Smith*
Shares of Anaplan soared after the cloud software company began trading on the New York Stock Exchange on Friday, despite making its debut at the tail end of one of the worst weeks for tech stocks in months.
Frank Calderoni, the CEO of Anaplan ($PLAN), attributed the stock's success to his company's sterling reputation among big businesses.
"It really shows that Anaplan, our platform, is really established in the business community to help them better make decisions in doing what they do," Calderoni said Friday in an interview on Cheddar.
Shares of Anaplan hit a high of over $24 per share after pricing shares at $17 apiece.
The company provides cloud-based enterprise software for financial and operations planning. It primarily targets mid- to large-sized clients, including HP ($HPQ) and Coca-Cola ($KO).
Through the IPO, Anaplan raised over $250 million in capital, which Calderoni said will be used to build new technology and invest in more foreign markets ー which already account for 40 percent of Anaplan's revenue.
"We're continuing to invest in our technology, so that we can keep it fresh and innovative over the next number of years," Calderoni said.
For full interview [click here](https://cheddar.com/videos/anaplan-soars-on-first-day-of-trading).
We may not be headed for a 2008-esque disaster, but increased geopolitical tension paired with the end of the tech boom means volatility could stick around.
The dreaded Netflix crackdown on profile sharing translated into a major boost in subscribers while the promised rate cuts seem to be a far off fantasy.
After the 2021 boom, IPO activity slowed down significantly, in part due to monetary policy – but things are getting moving again with tech-friendly companies like Iboutta and Rubrik making a public debut.
With an increasing demand for mental health services, one person wanted to change the therapy game. In 2017, CEO Alex Katz founded Two Chairs, a company that uses technology to match patients with the right therapist.
